Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group

Intellia Therapeutics (NASDAQ:NTLA) had its target price reduced by Canaccord Genuity Group from $54.00 to $48.00 in a report released on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

NTLA has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, January 22nd. Chardan Capital reiterated a “buy” rating and set a $26.00 target price on shares of Intellia Therapeutics in a report on Friday, February 27th. JonesTrading lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Wedbush dropped their price target on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Finally, Barclays reduced their price target on Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, November 7th. Ten equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics has an average rating of “Hold” and a consensus price target of $19.14.

Intellia Therapeutics Stock Down 11.9%

Shares of Intellia Therapeutics stock opened at $13.60 on Tuesday. The business has a 50 day moving average of $12.09 and a 200 day moving average of $13.10. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25. The company has a market cap of $1.61 billion, a PE ratio of -3.55 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The business had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. During the same period in the previous year, the firm earned ($1.27) EPS. The company’s quarterly revenue was up 78.4% compared to the same quarter last year. On average, research analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the transaction, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at approximately $9,332,852.19. The trade was a 3.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the transaction, the executive vice president owned 98,533 shares in the company, valued at approximately $907,488.93. This represents a 7.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 53,051 shares of company stock worth $488,600 in the last quarter. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in Intellia Therapeutics by 154.1% during the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after purchasing an additional 55,118 shares during the last quarter. Woodline Partners LP purchased a new position in shares of Intellia Therapeutics in the first quarter worth $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Intellia Therapeutics by 8.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after purchasing an additional 38,521 shares in the last quarter. Atria Investments Inc bought a new position in shares of Intellia Therapeutics during the second quarter valued at $96,000. Finally, Intellectus Partners LLC boosted its position in shares of Intellia Therapeutics by 3.8% during the second quarter. Intellectus Partners LLC now owns 85,975 shares of the company’s stock valued at $806,000 after buying an additional 3,150 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

More Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.